IP Library Granted Patent US 9,079,943
Granted Patent B2
US 9,079,943 · App. 14/229,736 · Granted Jul 14, 2015

TC-83-derived alphavirus vectors, particles and methods

Inventors: Jon O. Rayner (Apex, NC); Jonathan F. Smith (Cary, NC); Bolyn Hubby (Chapel Hill, NC); Elizabeth A. Reap (Durham, NC)
Assignee: ALPHAVAX, INC.
C07K14/005A61K39/21C12N7/00C12N15/86A61K48/00A61K2039/5256A61K2039/5258C12N2740/16222C12N2740/16234C12N2770/36143C12N2770/36162C12N2840/203
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,079,943
App. No.
14/229,736
Granted
Jul 14, 2015
Kind
B2
Abstract

The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.

Claims (12)

1. A composition comprising infectious, propagation-defective alphavirus particles, wherein the particles comprise Venezuelan equine encephalitis virus TC-83 structural proteins and an alphavirus replicon RNA, said alphavirus replicon RNA comprising an alphavirus packaging signal and one or more heterologous RNA sequence(s) encoding at least one immunogen, and said alphavirus replicon RNA lacking sequences encoding alphavirus structural proteins.

2. The composition of claim 1 , wherein the alphavirus replicon RNA is from Venezuelan equine encephalitis virus.

3. The composition of claim 1 , wherein there is one heterologous RNA sequence.

4. The composition of claim 1 further comprising a pharmaceutically-acceptable carrier.

5. The composition of claim 1 , wherein at least one of the structural proteins from Venezuelan equine encephalitis TC-83 has been modified to contain at least one additional attenuation mutation.

6. The composition of claim 2 , wherein the alphavirus replicon RNA is from Venezuelan equine encephalitis virus TC-83.

7. The composition of claim 1 , wherein there are two heterologous RNA sequences.

8. The composition of claim 1 further comprising a helper cell, wherein the helper cell comprises:

(a) an alphavirus replicon RNA encoding a heterologous RNA sequence and lacking sequences encoding alphavirus structural proteins;

(b) a first helper RNA encoding at least one, but not all Venezuelan equine encephalitis virus TC-83 structural proteins, and

(c) a second helper RNA not encoding at least one Venezuelan equine encephalitis virus TC-83 structural protein encoded by the first helper RNA and encoding at least one Venezuelan equine encephalitis virus TC-83 structural protein not encoded by the first helper RNA.

9. The composition of claim 8 wherein the alphavirus replicon RNA is a Venezuelan equine encephalitis virus TC-83 alphavirus replicon nucleic acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2015
From: RAYNER, JON O.; SMITH, JONATHAN F.; HUBBY, BOLYN; REAP, ELIZABETH A.
To: ALPHAVAX, INC
Reel/Frame 035767/0577 →
Continuity (4)
Division 12831017 · Jul 6, 2010
Continuation 11132711 · May 18, 2005
Provisional Application 60572212 · May 18, 2004
Related Publication 20140205629A1 · Jul 24, 2014